Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Klijn JG, et al. J Clin Oncol. 2001 Jan 15;19(2):343-53. doi: 10.1200/JCO.2001.19.2.343. J Clin Oncol. 2001. PMID: 11208825
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG, de Voogt HJ, Studer UE, Schröder FH, Sylvester R, De Pauw M. Klijn JG, et al. Cancer. 1993 Dec 15;72(12 Suppl):3858-62. doi: 10.1002/1097-0142(19931215)72:12+<3858::aid-cncr2820721719>3.0.co;2-6. Cancer. 1993. PMID: 8252504 Clinical Trial.
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens R, Heuson JC, Julien JP, Veyret C, Van Zyl J, Klijn JG, Sylvester R, Mignolet F. Paridaens R, et al. Among authors: klijn jg. J Clin Oncol. 1993 Sep;11(9):1723-8. doi: 10.1200/JCO.1993.11.9.1723. J Clin Oncol. 1993. PMID: 8355039 Clinical Trial.
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT. Bontenbal M, et al. Among authors: klijn jg. Br J Cancer. 1998 Jun;77(12):2257-63. doi: 10.1038/bjc.1998.375. Br J Cancer. 1998. PMID: 9649142 Free PMC article. Clinical Trial.
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. Among authors: klijn jg. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
Bontenbal M, van Putten WL, Burghouts JT, Baggen MG, Ras GJ, Stiegelis WF, Beudeker M, Janssen JT, Braun JJ, van der Linden GH, van der Velden PC, van Geel AN, Helle P, Leisink M, Foekens JA, Klijn JG. Bontenbal M, et al. Among authors: klijn jg. J Clin Oncol. 2000 Feb;18(4):734-42. doi: 10.1200/JCO.2000.18.4.734. J Clin Oncol. 2000. PMID: 10673514 Clinical Trial.
343 results